Sorriso Pharmaceuticals, a company focused on transforming anti-inflammatory antibody therapy, has closed on a $31 million Series A financing. The round was co-led by New Enterprise Associates (NEA), and Arix Bioscience plc.

Sorriso Pharmaceuticals is a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of inflammatory disease, including Crohn's disease and ulcerative colitis. The Sorriso platform generates potent antibodies that can be delivered orally and are designed to maintain activity throughout the intestinal system.